Work

Lasmiditan induces mitochondrial biogenesis in primary mouse renal peritubular endothelial cells and augments wound healing and tubular network formation

Year: 2025

Type: article

Abstract: Lasmiditan, an FDA-approved HTR1F agonist, induces mitochondrial biogenesis (MB) and enhances recovery following acute kidney injury in mice. Renal microvascular endothelial cells (MV-ECs) are highly susceptible to dysfunction/rarefaction postinjury. The effect of MB on MV-EC repair/recovery is unknown. We show that lasmiditan induces MB in primary mouse renal peritubular endothelial cells and improves wound healing, endothelial tubular network formation, and barrier integrity after inflammatory-induced dysfunction, indicative of its potential for the treatment of kidney diseases.

Source: American Journal of Physiology-Cell Physiology

DOI: 10.1152/ajpcell.00116.2025

Authors: Austin D. Thompson, Kai W. McAlister, Natalie E. Scholpa, Jaroslav Janda, John Hortareas, Rick G. Schnellmann

Institutions: University of Arizona, Southern Arizona VA Health Care System

Language: English

Topic: Acute Kidney Injury Research

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Veterans Affairs, National Institute of Environmental Health Sciences